Item 2.02 Results of Operations and Financial Condition.

On February 2, 2023, Bristol-Myers Squibb Company (the "Company") issued a press release (the "Earnings Press Release") announcing its financial results for the fourth quarter of 2022 and full year of 2022. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Also furnished pursuant to this Item 2.02 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety is certain supplemental information (the "Supplemental Information") posted on the Company's website at www.bms.com.

Item 7.01 Regulation FD Disclosure.

On February 2, 2023, the Company posted on its website at www.bms.com a presentation (the "Bristol Myers Presentation") on certain financial and operating initiatives available for viewing during the Company's conference call and webcast announcing its financial results for the fourth quarter of 2022 and full year of 2022 at 9:00 a.m. Eastern time on February 2, 2023. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. The Earnings Press Release and the Bristol Myers Presentation includes references to non-GAAP financial information. Reconciliations between the non-GAAP financial measures and the comparable GAAP financial measures are available in the Supplemental Information, which is included as Exhibit 99.2 hereto, and the reasons for the presentation of such non-GAAP financial measures are available in the Earnings Press Release, which is included as Exhibit 99.1 hereto. The Bristol Myers Presentation should be read in conjunction with the Supplemental Information and the Earnings Press Release. The Company reserves the right to discontinue availability of the Bristol Myers Presentation from its website at any time.

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:


  Exhibit
    No.           Description

   99.1           Press release of Bristol-Myers Squibb Company dated February 2, 2023.
   99.2           Certain supplemental information posted on Bristol-Myers Squibb Company's website
                  at www.bms.com not included in the press release.
   99.3           Presentation Materials of Bristol-Myers Squibb Company dated February 2, 2023.
                  The cover page from this Current Report on Form 8-K formatted in Inline XBRL
    104           (included as Exhibit 101).

© Edgar Online, source Glimpses